Zantac has been connected to high levels of a cancer-causing molecule. If you or a family member used Zantac for 6 months or more and developed cancer, you may be entitled to compensation. Some of the cancers that have been linked to Zantac are:
Scientific studies have demonstrated that ranitidine can transform into a cancer-causing molecule called N-nitrosodimethylamine (“NDMA”), which is part of a carcinogenic group of compounds called N-nitrosamines. Studies have shown that these compounds increase the risk of cancer in humans and animals The FDA, the Environmental Protection Agency, and the International Agency for Research on Cancer consider NDMA to be a probable human carcinogen.
Valisure LLC and ValisureRX LLC, a pharmacy and testing laboratory, filed a Citizen Petition on September 9, 2019, calling for the recall of all ranitidine products due to high levels of NDMA in the products. The FDA issued a statement on September 13 warning that some ranitidine products may contain NDMA. On November 1, the FDA announced that testing had revealed the presence of NDMA in ranitidine products. The FDA recommended that drug manufacturers recall ranitidine products with NDMA levels above the acceptable daily intake level. Id. Five months later, on April 1, 2020, the FDA requested the voluntary withdrawal of all ranitidine products from the market.
Zantac has been sold since the early 1980s, first by prescription and later as an OTC medication. In 1983, the U.S. Food and Drug Administration (“FDA”) approved the sale of prescription Zantac. GSK first developed and patented Zantac. Zantac was a blockbuster—the first prescription drug in history to reach $1 billion in sales.
GSK entered into a joint venture with Warner-Lambert in 1993 to develop an OTC form of Zantac. Beginning in 1995, the FDA approved the sale of various forms of OTC Zantac. The joint venture between GSK and Warner-Lambert ended in 1998, with Warner-Lambert retaining control over the sale of OTC Zantac in the United States and GSK retaining control over the sale of prescription Zantac in the United States. Pfizer acquired Warner-Lambert in 2000 and took control of the sale of OTC Zantac in the United States.
The right to sell OTC Zantac in the United States later passed to BI and then to Sanofi. When the patents on prescription and OTC Zantac expired, numerous generic drug manufacturers began to produce generic ranitidine products in prescription and OTC forms.
FDA is requesting a market withdrawal of all remaining prescription and OTC ranitidine products on the U.S. market. This means that ranitidine will not be available for use in the U.S. The agency is taking this action because FDA laboratory testing results show that levels of NDMA in ranitidine may increase to unacceptable levels over time. The tests also show NDMA levels increase in some ranitidine products when the drug is exposed to higher than room temperatures. Based on these findings, FDA has determined that many currently marketed ranitidine products could expose consumers to unacceptable health risks. All ranitidine products, including the oral liquid/syrup, will be withdrawn by their manufacturers and will not be available on the U.S. market.
To qualify for a claim you must have used Zantac for at least 6 months
Yes, all formulations of ranitidine are affected by this action.
Yes, compounded ranitidine products are affected by this action.
Expenses for hospital stays or doctor’s visits, surgeries, medical devices, and medication.